Shares of Altimmune Inc. (ALT) are surging over 20% in pre-market today, after the company announced that it has been awarded $4.7 million from the U.S. Army Medical Research & Development Command or USAMRDC to fund its Phase 1/2 clinical trial of T-COVID, an investigational intranasal immune modulator for the treatment of outpatients with early COVID-19.
from RTT - Before the Bell https://ift.tt/3eJ09Dd
via IFTTT
No comments:
Post a Comment